Utilization of gene-engineered T cells for enhancing cancer immunotherapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1041828

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2017

Funding Scheme: Research Fellowships

Funding Amount: $761,656.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cells | cancer therapy | gene therapy | immunology | tumour immunotherapy

Related Links